Skip to main content
TipRanks
Go Ultimate75% OFF

bioMerieux (0RUG) Share Price & Analysis

3 Followers

0RUG Stock Chart & Stats

€90.55-€1.35(-1.47%)
At close: 4:30 PM GMT
€70€80€90Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 90.30 - EUR 91.90
52-Week Range
EUR 65.90 - EUR 116.10
Previous Close
EUR 91.90
Volume
N/A
Average Volume (3M)
90.80K
Market Cap
EUR 10.85B
Enterprise Value
EUR 7.90B
Total Cash (Recent Filing)
EUR 657.70M
Total Debt (Recent Filing)
EUR 421.80M
Price to Earnings (P/E)
23.4
Beta
0.93
Next Earnings
Feb 26, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
1.06%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Low leverage and a substantial equity base reduce financial risk and give bioMérieux flexibility to fund research, product development, and commercial investment. This strengthens resilience through softer demand and supports sustained execution without relying heavily on external financing.

Installed-base Recurring Revenue Model

The combination of installed instruments, recurring consumables, and service revenue creates repeat purchasing tied to customer testing volumes. This platform model can deepen customer relationships, improve revenue visibility, and support durable economics as menus and utilization expand.

Rebounding Free Cash Flow

The sharp free-cash-flow recovery provides more internally generated funding for innovation, capacity, and shareholder or balance-sheet needs. Although consistency still matters, the 2025 step-up demonstrates that the business can convert operations into meaningful cash when conditions normalize.

Bears Say

Recent Revenue Contraction

Recent revenue contraction indicates that bioMérieux’s durable growth engine has temporarily weakened after expansion through 2024. If softer demand persists, slower instrument placements and consumable pull-through could limit operating leverage and reduce resources available for future investment.

Profitability And Return Moderation

Profitability remains positive, but declining net income and lower returns than earlier years show that earnings momentum has cooled. Continued margin or return pressure could reduce the benefit of the company’s installed-base economics and constrain reinvestment despite solid underlying margins.

Inconsistent Cash Conversion

Choppy cash generation makes financial planning less predictable and suggests that reported earnings have not always translated efficiently into cash. Working-capital or other conversion pressure could recur, weakening the funding available for strategic initiatives even after the 2025 recovery.

bioMerieux News

0RUG FAQ

What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest share price was €65.90 and its highest was €116.10 in the past 12 months.
What is bioMerieux’s market cap?
bioMerieux’s market cap is €10.85B.
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s next earnings report is estimated for Feb 26, 2027 (not yet confirmed), which is in 100 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Jul 28, 2026. The company reported €1.99 earnings per share for the quarter, missing the consensus estimate of €2.03 by -€0.04.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Overvalued.
Does bioMerieux pay dividends?
bioMerieux does not currently pay dividends.
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is 2.52.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of €1.99 in its last earnings report, missing expectations of €2.03. Following the earnings report the stock price went up 5.303%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in GB:0RUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology